Aligos Therapeutics, Inc.

ALGS • Biotechnology

$6.21

▼ -0.01 (-0.16%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$64.78M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 19.2%Nivel de deuda manejable · 0.1Liquidez saludable · 3.9Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 1:46 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$6.21

Change-0.16%

Shares Out10.43M

Market Cap$64.78M

Enterprise Value$37.90M

52W Range3.98 - 13.69

Beta2.26

P/E-0.92

P/S17.32

P/B2.03

P/FCF-0.69

EV/Sales10.13

Price$6.21

Change-0.16%

Shares Out10.43M

Market Cap$64.78M

Enterprise Value$37.90M

52W Range3.98 - 13.69

Beta2.26

P/E-0.92

P/S17.32

P/B2.03

P/FCF-0.69

EV/Sales10.13

EV/EBITDA-0.47

EV/FCF-0.40

Earnings Yield-108.59%

FCF Yield-145.92%

Dividend Yield0.00%

Gross Margin57.46%

Oper. Margin-40.25%

Profit Margin-11.07%

Debt/Eq0.10

Current Ratio3.90

Quick Ratio3.90

Target$20.00

Target Upside222.06%

Target Median$20.00

Target Range20.00 - 20.00

Volume10.68K

Avg Volume173.70K

EPS Surprise0.08

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

54/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 19.2%Nivel de deuda manejable · 0.1Liquidez saludable · 3.9Rentabilidad débil

Analyst view

Analyst sentiment and price target

ALGS

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

80/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$20.00

Promedio

$20.00

Mediana

$20.00

Alto

$20.00

Resumen de la compañía

IPO: 10/16/2020

Industria: Biotechnology

P/B i: 2.03

Deuda / Patrimonio i: 0.10

Margen operativo: -4024.93%

Margen neto: -1106.72%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.10

Ratio corriente: 3.90

Ratio rápido: 3.90

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Hirth Peter

Transacción: 06/25/2026

COMPRA

Cambio

+5,860

Precio

$5.50

Presentación

06/29/2026

Tipo

COMPRA

Nuechterlein Carole

Transacción: 06/25/2026

COMPRA

Cambio

+5,860

Precio

$5.50

Presentación

06/29/2026

Tipo

COMPRA

Scopa James Paul

Transacción: 06/25/2026

COMPRA

Cambio

+5,860

Precio

$5.50

Presentación

06/29/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Hirth Peter	COMPRA	+5,860	$5.50	06/25/2026	06/29/2026
Nuechterlein Carole	COMPRA	+5,860	$5.50	06/25/2026	06/29/2026
Scopa James Paul	COMPRA	+5,860	$5.50	06/25/2026	06/29/2026
Martell Bridget A	COMPRA	+5,860	$5.50	06/25/2026	06/29/2026
Chavez Margarita	COMPRA	+5,860	$5.50	06/25/2026	06/29/2026
Preston Heather	COMPRA	+5,860	$5.50	06/25/2026	06/29/2026
Symons Julian A.	COMPRA	+23,310	$7.03	03/09/2026	03/11/2026
BLATT LAWRENCE	COMPRA	+105,840	$7.03	03/09/2026	03/11/2026
Calhoun Lesley Ann	COMPRA	+37,485	$7.03	03/09/2026	03/11/2026
Aneja Nikhil	COMPRA	+9,450	$7.03	03/09/2026	03/11/2026
Aneja Nikhil	OTRO	+3,600	$8.68	01/29/2026	02/19/2026
Calhoun Lesley Ann	COMPRA	+40,185	$8.68	07/16/2025	07/18/2025
Symons Julian A.	COMPRA	+16,000	$8.68	07/16/2025	07/18/2025
BLATT LAWRENCE	COMPRA	+179,800	$8.68	07/16/2025	07/18/2025
Martell Bridget A	COMPRA	+5,860	$7.63	06/25/2025	06/26/2025
Chavez Margarita	COMPRA	+5,860	$7.63	06/25/2025	06/26/2025
Preston Heather	COMPRA	+5,860	$7.63	06/25/2025	06/26/2025
Hirth Peter	COMPRA	+5,860	$7.63	06/25/2025	06/26/2025
Scopa James Paul	COMPRA	+5,860	$7.63	06/25/2025	06/26/2025
Nuechterlein Carole	COMPRA	+5,860	$7.63	06/25/2025	06/26/2025

Sobre la compañía

Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.

Fuente - Link

Competidores

BRNS CVM FGEN INMB KZR MRSN OKUR SKYE TPST XFOR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Aligos Therapeutics, Inc. $ALGS Shares Bought by Bank of America Corp DE

Bank of America Corp DE grew its holdings in shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS) by 1,652.8% in the quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 229,754 shares of the company's stock after buying an additional 216,646 shares

Defense World

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference.

GlobeNewsWire

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of chronic hepatitis B virus (HBV) infection. The study is being conducted in China by Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), who maintain rights in Greater China.

GlobeNewsWire

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's second quarter 2026 financial results on Thursday, August 6, 2026, before the open of the U.S. financial markets.

GlobeNewsWire

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for the treatment of chronic hepatitis B virus (HBV) infection.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	-2.29	-2.21	0.08
2026-03-05	-2.48675	-1.91	0.57675
2025-11-06	-2.09	-3.04	-0.95
2025-08-06	-2.35	-1.53	0.82
2025-05-06	-2.8	-2.11	0.69
2025-03-10	-2.63	-3.41	-0.78
2024-11-06	-2.15	-3.07	-0.92
2024-08-06	-4	0.75	4.75
2024-05-07	-4.75	-5.5	-0.75
2024-03-12	-6.75	-5.5	1.25
2023-11-02	-12	-10.25	1.75
2023-08-03	-12.5	-10.75	1.75